An interventional study of Paxman Scalp Cooling System in Alopecia, sponsored by Charles Mays. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-20.
Sponsored by Charles Mays · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 216 studies in Alopecia with a site in United States — 43 open to participants now, 63 under way, 6 of them phase 3. Alopecia · United States.
Among the 216 studies in Alopecia with a site in United States, this one is the 37th largest by planned enrollment of the 203 interventional ones that give a count, is one of 14 that started in 2026, is one of 93 with no phase, reaches primary completion later than 32 of the 62 other live ones, and was the 204th registered.
512 studies on the registry are indexed under Alopecia; 129 are open to participants now.
Browse Alopecia studies →43 of the 216 studies in Alopecia with a site in United States are open now. Recruiting first, the newest first:
Pelage Pharmaceuticals, Inc. · Sites in United States, Canada
Ages 18–55 · Men only
Johns Hopkins University · Sites in United States
Ages 18–80
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
University of Miami · Sites in United States
Ages 18+
K. Kay Durairaj, MD, FACS, A Medical Corporation · Sites in United States
Ages 35–55 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
216 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 57 · Phase 3 17 · Phase 4 9
First in 2000; this study’s year is marked. 14 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 50 across 431 interventional studies indexed under Alopecia.
Median enrollment 40 across the 203 interventional studies, 204 across the 12 observational. Of the 126 that completed or were terminated, 52 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
123 of 216 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Charles Mays as lead sponsor.
Charles Mays has 1 study filed under Alopecia — fewer than ten, so there is no comparison to draw.
28 of the studies in Alopecia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06972264Phase 3Veradermics, Inc.Safety and Efficacy of VDPHL01 in Males With AGA | 2026-12 |
| NCT07146022Phase 3Veradermics, Inc.Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) | 2027-06 |
| NCT04207931Wake Forest University Health SciencesTreatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study | 2026-11 |
| NCT05416333Wake Forest University Health SciencesAzelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA) | 2026-11 |
| NCT07588243CynosureLutronicA Clinical Study to Evaluate the Efficacy and Safety of Ultra in Promoting Hair Regrowth | 2026-12 |
Add all 28 to your calendar (.ics) → With an account.
Among the 216 studies in Alopecia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This single-blind, randomized controlled trial is proposed to assess the effects of the PAXMAN Scalp Cooling System on the quality of life of breast cancer subjects receiving any treatment regimen consisting of a chemotherapy agent known to cause chemotherapy-induced alopecia (CIA). Quality of life will be measured using the Chemotherapy-Induced Alopecia Distress Scale (CADS) for cancer patients pre-and post-treatment. Simultaneously, the effect of scalp cooling on hair retention and regrowth will be determined by self-reported grading of photographic assessment using the Alopecia (Hair Loss) Pictorial Tool. Results will be correlated with presence of single nucleotide variations (SNVs) rs3820706 in the CACNB4 gene and rs1202179 in the ABCB1 gene. Participants will be blinded to genetic results until the completion of the study to prevent bias, as knowing results could influence the participants' behavior.
100 subjects, 50 per cohort: 1) Treatment Arm - receiving CIA treatment with the PAXMAN Scalp Cooling System and 2) Control Arm - No hair retention treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Receiving CIA treatment with the PAXMAN Scalp Cooling System
Device: Paxman Scalp Cooling System
No hair retention treatment
The Paxman Scalp Cooling System is a clinically proven medical device designed to prevent or reduce chemotherapy-induced alopecia (hair loss). It is FDA-cleared for use in patients with solid tumors, such as breast, ovarian, and prostate cancers.
Hair Retention and Regrowth
To determine whether the PAXMAN Scalp Cooling System is effective for improving the quality of life of breast cancer subjects in the Appalachian Highlands region. The Self-Reported Alopecia (Hair Loss) Pictorial Tool will be performed to specifically evaluate hair retention and regrowth (on Day 1 and post-treatment 4 weeks (± 1 week), 8 weeks (± 1 week), and 12 weeks (± 1 week)). Grading will be for 0 to 2, with 0 being No Significant Hair Loss, 1 being Hair Loss up to 50%, and 2 being Hair Loss \> 50% as judged by the participant (and referred to as self-reported).
Time frame: From enrollment to 12 weeks post-treatment with chemotherapy
Hair Retention and Chemotherapy-Induced Alopecia Distress
To determine whether the PAXMAN Scalp Cooling System is effective for improving the quality of life of breast cancer subjects in the Appalachian Highlands region. The Chemotherapy-Induced Alopecia Distress Scale (CADS) will be used to evaluate quality of life on Day 1 and post-treatment 12 weeks (± 1 week). The CADS assesses the psychosocial impact of hair loss due to chemotherapy, helping to understand a patient's level of psychological distress. It specifically measures various aspects of a patient's well-being, including physical, emotional, activeness, and relationship distress. The CADS is a 17-item self-report questionnaire that uses a four-point Likert scale (0 = Not at All, 1 = A Little, 2 = Quite a Bit, 3 = Very Much). The total score can range from 0 to 51, with higher scores indicating greater distress. Scores from 0 to 13 indicate low levels of distress, while scores of 14 or above indicate a high level of distress related to chemotherapy-induced alopecia.
Time frame: From enrollment to 12 weeks post-treatment with chemotherapy
Role of Single Nucleotide Variations
To determine the incidence rate and relevance of single nucleotide variations (SNVs) previously linked to CIA in Japanese and Spanish populations for the Appalachian Highlands region of the southeastern United States by sequencing analysis of rs3820706 in the CACNB4 gene and rs1202179 in the ABCB1 gene prior to chemotherapy treatment for all participants.
Time frame: From enrollment to 12 weeks post-treatment with chemotherapy
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Mar 2026; primary completion for Jan 2027, 10 months later.
Of 85 non-industry interventional studies with no phase under Alopecia, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 46. This study's planned 10 months is below that.
Counting every sponsor, half of 146 studies reached it within 12 months; a quarter within 6 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.